Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06423352
Study type Interventional
Source Alnylam Pharmaceuticals
Contact Alnylam Clinical Trial Information Line
Phone 1-877-ALNYLAM
Email clinicaltrials@alnylam.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date June 7, 2024
Completion date September 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT01601470 - Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension Phase 2
Recruiting NCT05530512 - Acupuncture Therapy and Hypertension N/A